Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2001
Business Overview: The Company operates two primary segments: Healthcare Distribution (dental, medical, veterinary, and international) and Technology (practice management software). It distributes healthcare products and services to office-based practitioners in North America, Europe, and the Pacific Rim.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Net Sales | $593.9 million | $554.1 million |
| Gross Profit | $159.4 million | $149.1 million |
| Gross Margin | 26.8% | 26.9% |
| Operating Income | $27.6 million | $23.5 million |
| Net Income | $14.1 million | $11.4 million |
| Diluted EPS | $0.33 | $0.28 |
| Cash and Equivalents | $38.1 million | $17.4 million (end of period) |
| Long-Term Debt | $253.9 million | $266.2 million (prior year end) |
| Operating Cash Flow | ($12.1 million) used | $8.9 million provided |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.2% ($39.8 million), driven primarily by a 7.4% increase in the Healthcare Distribution segment. The Medical business saw a 15.4% increase, while the Veterinary segment declined 4.5% due to a lost product line.
- Profitability: Operating income rose 17.5% to $27.6 million. While gross margin dipped slightly to 26.8%, the Technology segment margin improved significantly to 72.9%.
- Cash Flow: Operating cash flow turned negative ($12.1 million used) compared to positive cash flow in the prior year. This was primarily due to a $51.6 million decrease in accounts payable and accruals, attributed to payments for year-end inventory buy-ins.
- Debt Reduction: Long-term debt decreased by approximately $12.4 million compared to the prior year-end balance, and interest expense declined due to lower debt balances.
Outlook, Risks, and Management Commentary
- Liquidity: The Company maintains $38.1 million in cash and equivalents. It has a $150 million revolving credit facility (unused) and $30 million in uncommitted bank lines (unused). Subsidiary facilities total $51.6 million with $7.8 million borrowed.
- Capital Expenditures: Management expects to invest over $45.0 million in 2001 to modernize facilities and infrastructure.
- Restructuring: A restructuring plan announced in August 2000 (eliminating ~300 positions) was substantially completed by December 2000. Remaining accruals for severance and facility costs were $7.2 million as of March 31, 2001.
- Legal Proceedings: The Company is a defendant in approximately 68 product liability cases, including 52 involving latex glove allergies and 8 involving "Phen/fen" drugs. A class action lawsuit regarding practice management software (Easy Dental) is pending appeal in the Texas Supreme Court.
- Market Risks: Risks include foreign currency fluctuations (hedged via derivatives), Euro conversion impacts, and competitive pressures from e-commerce solutions.
Investor Verification Checklist
- Verify the sustainability of the Medical segment's 15.4% growth rate.
- Monitor the resolution of the Texas Supreme Court appeal regarding the Easy Dental class action lawsuit.
- Assess the impact of the negative operating cash flow on future working capital needs, specifically regarding inventory buy-ins.
- Review the status of indemnification agreements for the 68 pending product liability cases.
- Confirm the execution of the planned $45 million capital expenditure program for infrastructure modernization.